As a European preclinical neurology contract research organization (CRO), InnoSer provides you with a portfolio of Amyothropic Lateral Sclerosis (ALS) mouse models relevant for performing preclinical efficacy research studies. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs.  InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies). 

InnoSer offers multiple ALS mouse models relevant for preclinical research, including the SOD1-G93A transgenic ALS mouse model, TDP-43 transgenic mouse models and TDP-43 seeding models using recombinant or patient-derived seeds. However, as each model is unique, modelling distinct pathophysiological aspects of ALS, we recommend you discuss the most appropriate model with our neurology study directors.